Emergence Therapeutics AG
General information
Emergence Therapeutics AG
Schifferstrasse 210
47059 Duisburg, North Rhine-Westphalia
Germany
Contact person: Jack Elands, Chief Executive Officer
Website: https://emergencetx.com
Schifferstrasse 210
47059 Duisburg, North Rhine-Westphalia
Germany
Contact person: Jack Elands, Chief Executive Officer
Website: https://emergencetx.com
| Year founded: | 2019 |
| Source of foundation: | Joint venture |
| Name of foundation source: | Heidelberg Pharma Research GmbH and Kurma Partners |
Corporate description / mission:
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
State of ownership: Private / independent
Headquarters: Yes
Headquarters: Yes
Remarks on ownership / listings
Emergence has a subsidiary in Marseille, France.
Emergence has a subsidiary in Marseille, France.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Phase I: | 1 |
Description of products:
The company's lead investigational product is an ADC against nectin-4.
The company's lead investigational product is an ADC against nectin-4.
Technology used:
The company's lead program uses Heidelberg Pharma’s proprietary ATAC technology embracing antibody design, linker technology and the payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers.
The company's lead program uses Heidelberg Pharma’s proprietary ATAC technology embracing antibody design, linker technology and the payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers.
Collaborations & Clients
Partnering strategy / collaborations:
Emergence Therapeutics’ in-house expertise and team is supported by collaborations with world-class partners. These include:
An R&D collaboration with MimAbs SAS (Marseille, France) a biotechnology CRO for antibody research and development co-founded by François Romagné, co-founder and former CSO of Innate Pharma.
A collaboration with Marc Lopez, who discovered the nectin family of proteins, and Daniel Olive from the Cancer Research Center in Marseille (CRCM).
A licensing and collaboration agreement with SATT Sud-Est (the regional tech transfer office for the Aix-Marseille Université, CNRS and Inserm) through which the Company has been granted exclusive rights to a set of anti-Nectin-4 antibodies from Marc Lopez at the Cancer Research Center in Marseille (CRCM), France.
A license agreement with Mablink Bioscience SAS (Lyon, France) through which Emergence has access to novel linker technology.
A licensing and collaboration agreement with Heidelberg Pharma Research GmbH, a subsidiary of Heidelberg Pharma AG (Ladenburg, Germany). Through this agreement Emergence has access to Heidelberg Pharma’s proprietary ATAC technology including amanitin-based payloads. Heidelberg Pharma Research GmbH is also a founding investor in Emergence.
Emergence Therapeutics’ in-house expertise and team is supported by collaborations with world-class partners. These include:
An R&D collaboration with MimAbs SAS (Marseille, France) a biotechnology CRO for antibody research and development co-founded by François Romagné, co-founder and former CSO of Innate Pharma.
A collaboration with Marc Lopez, who discovered the nectin family of proteins, and Daniel Olive from the Cancer Research Center in Marseille (CRCM).
A licensing and collaboration agreement with SATT Sud-Est (the regional tech transfer office for the Aix-Marseille Université, CNRS and Inserm) through which the Company has been granted exclusive rights to a set of anti-Nectin-4 antibodies from Marc Lopez at the Cancer Research Center in Marseille (CRCM), France.
A license agreement with Mablink Bioscience SAS (Lyon, France) through which Emergence has access to novel linker technology.
A licensing and collaboration agreement with Heidelberg Pharma Research GmbH, a subsidiary of Heidelberg Pharma AG (Ladenburg, Germany). Through this agreement Emergence has access to Heidelberg Pharma’s proprietary ATAC technology including amanitin-based payloads. Heidelberg Pharma Research GmbH is also a founding investor in Emergence.
© 2023 Biotechgate by Venture Valuation